<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969201</url>
  </required_header>
  <id_info>
    <org_study_id>13EU/FSH01</org_study_id>
    <nct_id>NCT01969201</nct_id>
  </id_info>
  <brief_title>FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)</brief_title>
  <acronym>FAST</acronym>
  <official_title>Randomised Clinical Trial Comparing Highly Purified FSH Formulation (Fostimon®) and Recombinant FSH (Gonal-F®) in GnRH-antagonist Controlled Ovarian Hyperstimulation Cycles.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety
      of two different subcutaneous FSH preparations (Fostimon versus Gonal-F) for controlled
      ovarian hyperstimulation in a GnRH-antagonist cycle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>A clinical pregnancy is defined as a pregnancy showing ultrasound embryonic heart activity at 8 weeks of gestation;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Follicles &gt;16 mm on the Day of hCG Injection</measure>
    <time_frame>10-15 days after starting FSH stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Oocytes Retrieved</measure>
    <time_frame>end of treatment period, approximately 2 - 3 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate</measure>
    <time_frame>end of treatment period, approximately 2 - 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Quality (Number of Top Quality Embryos Transferred Per Patient)</measure>
    <time_frame>On culture day 3</time_frame>
    <description>The embryo quality evaluation will be performed on culture day 3, just before embryo transfer and will consist in the assessment of blastomeres number and 2 embryo morphology parameters: degree of fragmentation and cell division aspect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Serum Pregnancy Test Rate</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <description>Two weeks after embryo transfer, a serum pregnancy test will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery Rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Pregnancy Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Patients who will not get pregnant during the study, will be allowed to perform a frozen embryo transfer. Cumulative pregnancy rate will include also pregnancies achieved after a frozen embryo transfer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">710</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Fostimon®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-F®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urofollitrophin</intervention_name>
    <arm_group_label>Fostimon®</arm_group_label>
    <other_name>human derived follicle stimulation hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitrophin alpha</intervention_name>
    <arm_group_label>Gonal-F®</arm_group_label>
    <other_name>Recombinant follicle stimulation hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-38 years old;

          -  BMI: 18-28 kg/m2;

          -  Less than 3 previously completed IVF cycles;

          -  Basal FSH &lt;10 IU/L and E2 &lt;80 pg/ml;

          -  TSH &lt; 2.5 mIU/L

          -  &gt;10 and &lt;30 antral follicles 2-10 mm in size for both ovaries combined

          -  AMH: &gt;1 ng/ml (7.15 pmol/l) and &lt;5.6 ng/ml (40.0 pmol/l)

          -  Presence and adequate visualization of both ovaries;

          -  Within 12 months of the beginning of the study, uterine cavity consistent with
             expected normal function as assessed through transvaginal ultrasound,
             hysterosalpingogram, sonohysterogram or hysteroscopic examination;

        Exclusion Criteria:

          -  Primary ovarian failure or women known as poor responders;

          -  PCO and PCOS;

          -  Severe OHSS in a previous COH cycle;

          -  Uterine malformation that may impair the possibility to get pregnant;

          -  Ovarian cysts &gt;10 mm;

          -  Hydrosalpinx that have not been surgically removed or ligated;

          -  Endometriosis stage 3 or 4;

          -  Oocyte donation;

          -  Severe male factor;

          -  Pathologies associated with any contraindication of being pregnant;

          -  History of recurrent miscarriage (more than 3 previous miscarriages);

          -  Hypersensitivity to the study medication;

          -  Abnormal bleeding of undetermined origin;

          -  Uncontrolled thyroid or adrenal dysfunction;

          -  Neoplasias;

          -  Severe impairment of renal and/or hepatic function.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Barri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Universitari Dexeus, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Blockeel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Brussel, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL- Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ca'Granda, Osp Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli 'Federico II'</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica IVI Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ginefiv Clínica de Fertilidad</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Infertilidad (IVI)</name>
      <address>
        <city>Sevilla</city>
        <zip>40011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde</name>
      <address>
        <city>Bern</city>
        <state>Be</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Bülent Urman</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Fertility Services</name>
      <address>
        <city>Aldridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>December 12, 2018</results_first_submitted>
  <results_first_submitted_qc>September 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2019</results_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In vitro fertilization (IVF)</keyword>
  <keyword>Assisted reproduction technologies (ART)</keyword>
  <keyword>GnRH-antagonist</keyword>
  <keyword>Follicle stimulating hormone (FSH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fostimon®</title>
          <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
        </group>
        <group group_id="P2">
          <title>Gonal-F®</title>
          <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fostimon®</title>
          <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
        </group>
        <group group_id="B2">
          <title>Gonal-F®</title>
          <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="352"/>
            <count group_id="B2" value="358"/>
            <count group_id="B3" value="710"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.39" spread="3.83"/>
                    <measurement group_id="B2" value="32.68" spread="3.52"/>
                    <measurement group_id="B3" value="32.53" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="710"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="339"/>
                    <measurement group_id="B3" value="675"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Pregnancy Rate</title>
        <description>A clinical pregnancy is defined as a pregnancy showing ultrasound embryonic heart activity at 8 weeks of gestation;</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate</title>
          <description>A clinical pregnancy is defined as a pregnancy showing ultrasound embryonic heart activity at 8 weeks of gestation;</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.93"/>
                    <measurement group_id="O2" value="39.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was evaluated by calculating the 95% CI for the differences in pregnancy rates between the two treatment groups. If the lower bound of the 95% CI of the difference between the two proportions was greater than -0.10 (i.e. 10%), then Fostimon was to be considered not inferior to the control treatment.</non_inferiority_desc>
            <p_value>0.49</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.88</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Follicles &gt;16 mm on the Day of hCG Injection</title>
        <time_frame>10-15 days after starting FSH stimulation</time_frame>
        <population>Subject with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Follicles &gt;16 mm on the Day of hCG Injection</title>
          <population>Subject with available data.</population>
          <units>follicles &gt;16 mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="2.47"/>
                    <measurement group_id="O2" value="4.47" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Oocytes Retrieved</title>
        <time_frame>end of treatment period, approximately 2 - 3 weeks.</time_frame>
        <population>subjects who underwent oocytes retrieval</population>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Oocytes Retrieved</title>
          <population>subjects who underwent oocytes retrieval</population>
          <units>oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="4.72"/>
                    <measurement group_id="O2" value="9.33" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertilization Rate</title>
        <time_frame>end of treatment period, approximately 2 - 3 weeks</time_frame>
        <population>subjects with at least one oocyte inseminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Fertilization Rate</title>
          <population>subjects with at least one oocyte inseminated.</population>
          <units>percentage of oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.98" spread="26.44"/>
                    <measurement group_id="O2" value="75.85" spread="21.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embryo Quality (Number of Top Quality Embryos Transferred Per Patient)</title>
        <description>The embryo quality evaluation will be performed on culture day 3, just before embryo transfer and will consist in the assessment of blastomeres number and 2 embryo morphology parameters: degree of fragmentation and cell division aspect.</description>
        <time_frame>On culture day 3</time_frame>
        <population>Subject with at least one embryo transferred, with embryo scoring available.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Quality (Number of Top Quality Embryos Transferred Per Patient)</title>
          <description>The embryo quality evaluation will be performed on culture day 3, just before embryo transfer and will consist in the assessment of blastomeres number and 2 embryo morphology parameters: degree of fragmentation and cell division aspect.</description>
          <population>Subject with at least one embryo transferred, with embryo scoring available.</population>
          <units>Top embryos</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.64"/>
                    <measurement group_id="O2" value="0.48" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Serum Pregnancy Test Rate</title>
        <description>Two weeks after embryo transfer, a serum pregnancy test will be performed.</description>
        <time_frame>2 weeks after embryo transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Serum Pregnancy Test Rate</title>
          <description>Two weeks after embryo transfer, a serum pregnancy test will be performed.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                    <measurement group_id="O2" value="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delivery Rate</title>
        <time_frame>9 months</time_frame>
        <population>For 4 patients, 3 allocated to the Fostimon® group and 1 allocated to the Gonal-F® group this information was not available because of lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Delivery Rate</title>
          <population>For 4 patients, 3 allocated to the Fostimon® group and 1 allocated to the Gonal-F® group this information was not available because of lost to follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Pregnancy Rate</title>
        <description>Patients who will not get pregnant during the study, will be allowed to perform a frozen embryo transfer. Cumulative pregnancy rate will include also pregnancies achieved after a frozen embryo transfer.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostimon®</title>
            <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
          </group>
          <group group_id="O2">
            <title>Gonal-F®</title>
            <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Pregnancy Rate</title>
          <description>Patients who will not get pregnant during the study, will be allowed to perform a frozen embryo transfer. Cumulative pregnancy rate will include also pregnancies achieved after a frozen embryo transfer.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from the signature of the informed consent to the end-of-trial (i.e. up to 9 months in case of a positive pregnancy).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fostimon®</title>
          <description>75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
Urofollitrophin</description>
        </group>
        <group group_id="E2">
          <title>Gonal-F®</title>
          <description>75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
Follitrophin alpha</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>intra abdominal haemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>peritoneal haemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion early</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>abortion missed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>abortion spontaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cervical incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>ectopic pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>gestational diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>imminent abortion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Multiple pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Oligohydramniosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Placenta praevia haemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>premature delivery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>premature labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>premature rupture of membranes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vomiting in pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="352"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="352"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="352"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="352"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Leader</name_or_title>
      <organization>IBSA Insitut Biochimique</organization>
      <phone>+41 58 360 10 00</phone>
      <email>rd@ibsa.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

